By Connor Hart
Shares of Arvinas fell after the company said its in-development treatment for breast cancer didn't reach statistical significance in improving progression-free survival for its intent-to-treat population.
The stock declined 9.7%, to $6.50, in pre-market trading Monday. Shares ended Friday's regular session 4% lower, at $7.20, having lost about three-quarters of their value in the past year.
The biotechnology said that the therapy, vepdegestrant, notched a progression-free survival rate of 3.7 months in a recent Phase 3 study, compared with a progression-free survival rate of 3.6 months for fulvestrant, an existing breast cancer treatment.
Arvinas noted that vepdegestrant, which is being developed alongside Pfizer to treat certain types of advanced or metastatic breast cancer, was generally well tolerated in the clinical trial, and that the therapy did demonstrate a meaningful improvement in progression-free survival among estrogen receptor 1 mutation patients.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
June 02, 2025 07:16 ET (11:16 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.